Bionomics Limited , a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of cancer and diseases of the central nervous system, today announced the presentation of data from three of its most advanced oncology programs at the upcoming American Association for Cancer Research 106 Annual Meeting being held from April 18-22, 2015 in Philadelphia, PA USA. The presentation on the BNC105 program describes biomarker data obtained from clinical trials in three indications including renal cancer, ovarian cancer and mesothelioma.
